Back to top
more

Dextera Surgical Inc. (DXTR)

(Delayed Data from OTC)

$0.05 USD

0.05
1,486,069

+0.01 (42.57%)

Updated May 7, 2018 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2

DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.

    C.R. Bard Shareholders Approve Merger With Becton, Dickinson

    C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).

      Luminex (LMNX) Beats Earnings & Revenue Estimates in Q2

      Luminex's (LMNX) assay business will be its key driver over the long term. The FDA go-ahead for Luminex ARIES Bordetella and ARIES C. Difficile assay were the key highlights of the second quarter.

        Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top

        Evolent Health's (EVH) strong rise in the number of members on its platform was the key highlight of the second quarter.

          Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss

          Envision Healthcare's (EVHC) second-quarter results were positively impacted by strong Physician Services segment.

            4 Medical Product Stocks Likely to Top Q2 Earnings Estimates

            There are some powerful long-term tailwinds in the medical space.

              Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3

              Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.

                PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance

                PerkinElmer (PKI) posts tepid numbers in second quarter with in-line earnings and revenues missing the mark.

                  Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?

                  Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.

                    Becton, Dickinson (BDX) Beats on Q3 Earnings, Guidance Solid

                    Becton, Dickinson and Company's (BDX) solid adjusted earnings guidance is likely to boost investor confidence. Solid revenue performance in the Life Sciences segment is a key third-quarter highlight.

                      Fresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact

                      Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.

                        Can CVS Health (CVS) Pull a Surprise this Earnings Season?

                        CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.

                          MedTech Stocks to Top Q2 Estimates

                          Most of the MedTech majors are lined up to report their earnings results over the next week.

                            What's in the Offing for Hologic (HOLX) in Q3 Earnings?

                            Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.

                              What's in the Cards for DaVita (DVA) this Earnings Season?

                              Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.

                                Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?

                                Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.

                                  LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?

                                  With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.

                                    What's in Store for athenahealth (ATHN) in Q2 Earnings?

                                    athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.

                                      Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?

                                      Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.

                                        Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?

                                        Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.

                                          Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?

                                          Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.

                                            Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates

                                            Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.

                                              SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1

                                              Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.

                                                Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated

                                                Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.

                                                  Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3

                                                  Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.